Skip to main content
SpringerLink
Log in

The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT)

  • Original Research
  • Published:
Journal of Radiation Oncology

Abstract

Objective

Stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) is safe and effective in Child Pugh (CP) A cirrhosis, though a subset of patients may be at higher risk for progressive liver failure. The albumin-bilirubin (ALBI) model is a simple, novel, and validated prognostic assessment of hepatic cirrhosis in patients with HCC, but its utilization during liver SBRT is not well studied. Compared to conventional stratifications of cirrhosis, we hypothesize that the ALBI model is a sensitive predictor of hepatic function, survival, and liver failure following definitive SBRT for HCC in patients with CP-A cirrhosis.

Methods

From 2009 to 2016, 40 patients with HCC and CP-A cirrhosis completed SBRT. The mean dose was 45 Gy (40 to 50 Gy) in 4–5 fractions. Local control defined as the absence of tumor progression was assessed with CT or MRI every 3–6 months after SBRT. ALBI, MELD (model of end stage liver disease), and CP scores were recorded before treatment and every 3–4 months after. ALBI scores were calculated from the formula (log(bilirubin[mcmol/L]) × 0.66) − (albumin[g/L] × 0.085) and classified as ALBI-1, ALBI-2, or ALBI-3. Initial scores were measured against progression to CP-B cirrhosis and survival. Kaplan-Meier statistical analysis was conducted via MedCalc software.

Results

Forty patients with 49 HCC lesions were analyzed in this IRB approved retrospective study. Median tumor diameter was 3.5 cm (1.4–8.9 cm). Eight patients underwent orthotropic liver transplant (median time to transplant was 12 months). Prior to SBRT, 17 patients had ALBI-1 and 23 had ALBI-2 scores.The actuarial local control at 2 years was 98%. With the median follow-up of 23.4 months, overall survival (OS) was 92 and 60% at 1 and 2 years. Freedom from progression to CP-B was 74 and 62% at 1 and 2 years. Compared to pre-treatment ALBI-2 patients, ALBI-1 patients correlated with higher freedom from CP progression (HR = 3.66, P = 0.03), but not OS (P = 0.09). At the last follow-up, 22 of 40 patients (55%) progressed to a higher ALBI grade (12 from ALBI-1 to 2 and 10 from ALBI-2 to ALBI-3). The 2-year OS for patients with an ALBI-1 (n = 5), ALBI-2 (n = 25), and ALBI-3 (n = 10) at last follow-up was 80, 74, and 30%, respectively (P = 0.03).

Conclusion

Our study indicates that the ALBI index more precisely predicted liver failure and survival in HCC following SBRT compared to CP scoring. Its application may help select the most ideal candidates for SBRT among the often heterogeneous CP-A population. Further study regarding precautionary measures such as functional treatment planning for ALBI-2 patients treated with liver SBRT may be warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. El-Serag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60:1767–1775

    Article  Google Scholar 

  2. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  CAS  Google Scholar 

  3. Citterio D, Facciorusso A, Sposito C, Rota R, Bhoori S, Mazzaferro V (2016) Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma. JAMA Surg 151:846–853

    Article  Google Scholar 

  4. Child CG (1964) Remote results of portal surgery in liver cirrhosis. Rev Int Hepatol 14:287–288

    CAS  PubMed  Google Scholar 

  5. D'Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231

    Article  Google Scholar 

  6. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 31:1631–1639

    Article  Google Scholar 

  7. Cardenes HR, Price TR, Perkins SM et al (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol: Off Publ Fed Spanish Oncol Soc Natl Canc Inst Mexico 12:218–225

    Article  CAS  Google Scholar 

  8. Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45:831–837

    Article  Google Scholar 

  9. Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, Kwo P, Cárdenes H (2015) Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 5:e443–e449

    Article  Google Scholar 

  10. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol : Off J Am Soc Clin Oncol 33:550–558

    Article  Google Scholar 

  11. Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H (2016) Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 31:1031–1036

    Article  CAS  Google Scholar 

  12. Kirichenko A, Gayou O, Parda D, Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J, Monga D, Raj M, Thai N (2016) Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB: Off J Int Hepato Pancreato Biliary Assoc 18:88–97

    Article  Google Scholar 

  13. Gayou O, Day E, Mohammadi S, Kirichenko A (2012) A method for registration of single photon emission computed tomography (SPECT) and computed tomography (CT) images for liver stereotactic radiotherapy (SRT). Med Phys 39:7398–7401

    Article  Google Scholar 

  14. Hasan STN, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko AV (2017) Hepatocellular carcinoma with Child Pugh-A cirrhosis treated with stereotactic body radiotherapy. World J Gastrointes Surg 9:256–263

    Article  Google Scholar 

  15. Toesca DAS, Osmundson EC, von Eyben R, Shaffer JL, Koong AC, Chang DT (2017) Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol 7:173–182

    Article  Google Scholar 

  16. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol: Off J Am Soc Clin Oncol 27:1572–1578

    Article  Google Scholar 

  17. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493

    Article  Google Scholar 

  18. Kudithipudi V, Day E, Thai N et al (2017) Liver stereotactic radiotherapy (SRT) with functional treatment planning for patients with intermediate stage hepatocellular carcinoma (HCC). J Radiat Oncol 6:371–377

    Article  Google Scholar 

  19. Xu ZY, Liang SX, Zhu J, Zhu XD, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL (2006) Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65:189–195

    Article  Google Scholar 

  20. Fleming KM, Aithal GP, Card TR, West J (2012) All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int: Off J Int Ass Stud Liver 32:79–84

    Article  Google Scholar 

  21. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol : Off J Am Soc Clin Oncol 26:657–664

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA

    S. Hasan, Stephen Abel & A. V. Kirichenko

  2. Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA

    Imraan Jan

  3. Division of Transplant Surgery, Allegheny General Hospital, Philadelphia, PA, USA

    Tadahiro Uemura & N. Thai

Authors
  1. S. Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Abel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Imraan Jan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tadahiro Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Thai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. V. Kirichenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Imraan Jan.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hasan, S., Abel, S., Jan, I. et al. The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT). J Radiat Oncol 7, 247–253 (2018). https://doi.org/10.1007/s13566-018-0354-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-018-0354-7

Keywords

Search

Navigation